Proposed technology appraisals

Suggested remit

To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

3 July 2017 – 31 July 2017

Batch

Cancer

ID number

1066

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of axicabtagene ciloleucel within its marketing authorisation for treating relapsed or refractory diffuse large B-cell non-Hodgkin lymphoma.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

28 June 2017 – 26 July 2017

Batch

Cancer

ID number

1115

Scoping workshop

Tuesday 29 August 2017 (morning) in (London)

Suggested remit

To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating recurrent or metastatic squamous cell carcinoma of the head and neck.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

28 June 2017 – 26 July 2017

Batch

Cancer

ID number

1140

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of pertuzumab within its marketing authorisation for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

20 June 2017 – 18 July 2017

Batch

Cancer

ID number

1192

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating locally advanced or metastatic urothelial carcinoma in people for whom cisplatin-based chemotherapy is unsuitable.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

16 June 2017 – 14 July 2017

Batch

Cancer

ID number

1209

Scoping workshop

No workshop - consultation only.

Suggested remit

To appraise the clinical and cost effectiveness of ixekizumab within its marketing authorisation for treating active psoriatic arthritis in adults whose disease has not responded adequately to previous disease-modifying anti-rheumatic drug therapy.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

31 May 2017 – 28 June 2017

Batch

55

ID number

1194

Scoping workshop

No workshop - consultation only.

Suggested remit

To appraise the clinical and cost effectiveness of naldemedine within its marketing authorisation for treating opioid-induced constipation.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

31 May 2017 – 28 June 2017

Batch

55

ID number

1189

Scoping workshop

No workshop - consultation only.

Suggested remit

To appraise the clinical and cost effectiveness of ertugliflozin monotherapy within its marketing authorisation for treating type 2 diabetes.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

30 May 2017 – 27 June 2017

Batch

55

ID number

1158

Scoping workshop

No workshop - consultation only.

Suggested remit

To appraise the clinical and cost effectiveness of combination therapy with ertugliflozin within its marketing authorisation for treating type 2 diabetes.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

30 May 2017 – 27 June 2017

Batch

55

ID number

1159

Scoping workshop

No workshop - consultation only.

Suggested remit

To appraise the clinical and cost effectiveness of tildrakizumab within its marketing authorisation for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

25 May 2017 – 23 June 2017

Batch

55

ID number

1060

Scoping workshop

No workshop - consultation only.

Suggested remit

To appraise the clinical and cost effectiveness of erenumab within its marketing authorisation for preventing migraine.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

25 May 2017 – 23 June 2017

Batch

55

ID number

1188

Scoping workshop

No workshop - consultation only.

Suggested remit

To appraise the clinical and cost effectiveness of inhaled alpha-1 antitrypsin within its marketing authorisation for treating emphysema.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

24 May 2017 – 22 June 2017

Batch

55

ID number

1200

Scoping workshop

The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of inhaled alpha-1 antitrypsin for treating emphysema ID1200 We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.

The company that develop Inhaled alpha-1 antitrypsin have advised NICE that they have withdrawn their marketing authorisation application for this product for this indication and plan to resubmit their application in few years after collecting additional data from a planned phase 3 study. In light of this information, the Institute will not be progressing with the scoping exercise. Consequently, the scoping workshop arranged for Friday 14 July 2017 has been cancelled.

If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar on 44 (0)20 7045 2239 or via email on michelle.adhemar@nice.org.uk.

Suggested remit

To appraise the clinical and cost effectiveness of mepolizumab within its marketing authorisation for treating eosinophilic granulomatosis with polyangiitis.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

17 May – 15 June 2017

Batch

55

ID number

1186

Scoping workshop

Wednesday 5 July 2017 (morning) in (London)

Suggested remit

To appraise the clinical and cost effectiveness of epoetin alfa within its marketing authorisation for treating anaemia in people with myelodysplastic syndromes.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

17 May – 15 June 2017

Batch

55

ID number

1035

Scoping workshop

Wednesday 5 July 2017 (afternoon) in (London)

Suggested remit

To appraise the clinical and cost effectiveness of caplacizumab marketing authorisation for treating acute acquired thrombotic thrombocytopenic purpura.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

16 May – 14 June 2017

Batch

55

ID number

1185

Scoping workshop

Tuesday 4 July 2017 (afternoon) in (London)

Suggested remit

To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating previously treated metastatic gastric or gastro-oesophageal junction cancer.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

3 May – 1 June 2017

Batch

B53

ID number

1168

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of guselkumab within its marketing authorisation for treating moderate to severe plaque psoriasis.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

27 March – 26 April 2017

Batch

54

ID number

1075

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of plitidepsin in combination with dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

20 April – 19 May 2017

Batch

B53

ID number

1081

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of gemtuzumab ozogamacin within its marketing authorisation for untreated acute myeloid leukaemia.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

12 April – 15 May 2017

Batch

B53

ID number

982

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of avatrombopag within its marketing authorisation for treating thrombocytopenia in chronic liver disease.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

29 March – 28 April 2017

Batch

54

ID number

1105

Scoping workshop

The National Institute for Health and Care Excellence (NICE) has been invited to consider an appraisal of avatrombopag for thrombocytopenia in chronic liver disease ID1105. We recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.

Based on information from the company during the consultation, NICE has agreed that a scoping workshop at this time should be postponed, therefore as a consequence the workshop arranged for Friday 19 May 2017 has been cancelled and will be rearranged at a later date. We apologise for any inconvenience this may cause.

If you have any comments or concerns contact the project manager for this appraisal, Samantha Shannon, on (0)161 413 4081 or via email on samantha.shannon@nice.org.uk.

Suggested remit

To appraise the clinical and cost effectiveness of benralizumab within its marketing authorisation for treating inadequately controlled severe asthma with elevated blood eosinophils.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

29 March – 28 April 2017

Batch

54

ID number

1129

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of autologous haematopoietic stem cell transplantation (AHSTC) for previously treated relapsing-remitting multiple sclerosis.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

28 March – 27 April 2017

Batch

54

ID number

1111

Scoping workshop

Wednesday 17 May 2017 (morning) in (London)

Suggested remit

To appraise the clinical and cost effectiveness of ATIR101 as an adjunct to haematopoietic stem cell transplantation within its marketing authorisation for haematological cancers.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

23 March – 21 April 2017

Batch

54

ID number

1093

Scoping workshop

Friday 12 May 2017 (afternoon) in (London)

Suggested remit

To appraise the clinical and cost effectiveness of fluocinolone acetonide micro-insert within its marketing authorisation for treating recurrent non-infectious uveitis.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

23 March – 21 April 2017

Batch

54

ID number

1039

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of denosumab within its marketing authorisation for treating glucocorticoid-induced osteoporosis.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

17 March – 18 April 2017

Batch

54

ID number

1095

Scoping workshop

The National Institute for Health and Care Excellence (NICE) has been invited to consider an appraisal of denosumab for treating glucocorticoid-induced osteoporosis ID1095. We recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.

Following on from stakeholder consultation NICE has agreed that a scoping workshop at this time would not be appropriate therefore the scoping workshop arranged for Monday 8 May 2017 has been cancelled. We apologise for any inconvenience this may cause.

If you have any comments or concerns contact Samantha Shannon, the project manager for this appraisal, on (0)161 413 4081 or via email at samantha.shannon@nice.org.uk.

Suggested remit

To appraise the clinical and cost effectiveness of sunitinib within its marketing authorisation for treating renal cell carcinoma at high risk of recurrence after surgery.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

16 March – 13 April 2017

Batch

B53

ID number

1076

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of glecaprevir-pibrentasvir within its marketing authorisation for treating chronic hepatitis C.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

24 January – 21 February 2017

Batch

53

ID number

1085

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of brodalumab within its marketing authorisation for treating moderate to severe plaque psoriasis.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

24 January – 21 February 2017

Batch

53

ID number

878

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of dupilumab within its marketing authorisation for treating moderate to severe atopic dermatitis.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

20 January – 17 February 2017

Batch

53

ID number

1048

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of recombinant human parathyroid hormone within its marketing authorisation for treating hypoparathyroidism.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

20 January – 17 February 2017

Batch

53

ID number

1094

Scoping workshop

No workshop - consultation only

Suggested remit

To appraise the clinical and cost effectiveness of idebenone within its marketing authorisation for treating Duchenne muscular dystrophy.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

19 January – 16 February 2017

Batch

53

ID number

1092

Scoping workshop

Friday 10 March 2017 (morning) in (London)

Suggested remit

To appraise the clinical and cost effectiveness of andexanet alfa within its marketing authorisation for reversing anticoagulation.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

19 January – 16 February 2017

Batch

53

ID number

1101

Scoping workshop

Friday 10 March 2017 (afternoon) in (London)

Suggested remit

To appraise the clinical and cost effectiveness of netarsudil within its marketing authorisation for treating open angle glaucoma and ocular hypertension.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

19 January – 16 February 2017

Batch

53

ID number

1078

Scoping workshop

The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of Glaucoma (open-angle), ocular hypertension - netarsudil ID1078. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.

The consultation on the draft scope closed on Thursday 16 February 2017. After careful review of the consultation comments received NICE has agreed that a scoping workshop would not be appropriate at this time. As a consequence of this, the scoping workshop arranged for Monday 13 March 2017 has been cancelled. We apologise for any inconvenience this may cause. The workshop will likely be rearranged for early - mid next year.

If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar on 020 7045 2239 or via email on michelle.adhemar@nice.org.uk.

Background

In 2010 the Department of Health asked NICE to explore with stakeholders what value NICE can add in advising the NHS on the clinical and cost effectiveness of Avastin (bevacizumab) to treat wet age-related macular degeneration, the leading cause of blindness in the UK, and other conditions affecting the eye.

Consultation on briefing document and provisional list of stakeholders

02 June 2010 – 30 June 2010

Exploratory workshop

13 July 2010 in Manchester

Suggested remit

Venetoclax for treating chronic lymphocytic leukaemia associated with a 17p deletion or TP53 mutation

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

12 February – 11 March 2016

Batch

47

ID number

944

Scoping workshop

Please note there will be no workshop for this topic.